The immune response after the administration of CADI-05 is linked to an enhancement in tumor immune infiltrate (TII) and a shift in the tumor immune microenvironment from immunosuppressive (decrease in FoxP3, PD-1, and CTLA4-expressing immune cells) to immunostimulatory (increase in activated CD8+T cells, macrophages, and NK cells) [11,12]. The gene discussed is PDCD1; the disease is neoplasm.